Brand of the Year
Pharm Exec editors survey the brand landscape and choose the one drug that stands out from the competition by meeting a truly unmet medical need, enhancing treatment options for providers and physicians, and attracting fresh interest from patients through state of the art messaging and marketing appeal. Will it be a older drug with staying power or a new medicine with the clout to pass the test with payers? Check our February cover to see.

Fresh Currents in Cancer Dscovery, Development and Access
A dozen industry and stakeholder experts meet at New York's Alexandria Center for Life Sciences to review the latest advances in onocology research and discuss key challenges to transforming the best of new science into treatments that qualify for reimbursement in a tough fiscal climate. A wish list of policy recommendations to drive deciisions in the internal business and among governments and regulators is put forward in print and online -- in time for readers to engage in the debate over a condition that may someday soon be regarded as a chronic disease rather a death sentence.

Expert insight: PE Columns
Our roster of best practices viewpoints will focus on making sense of recent US patent case rulings, new technologies to increase patient adherence, and the latest inside info on promo agency-drug company relationships.